By Diagnostics World Staff
September 15, 2015 | Foundation Medicine today announced the launch of its precision medicine partner program, Precision Medicine Exchange Consortium (PMEC), to facilitate data exchange, advance research, and support education and applications of precision medicine in oncology and molecular pathology.
PMEC hopes to bring together oncology thought leaders from academic medical centers, regional hospital systems, and community oncology networks—initially in the U.S. but to be expanded internationally—who share a vision for using precision medicine as a means for improving clinical outcomes in oncology treatment through a collaborative exchange of molecular information and clinical outcomes data, and through a broader integration of comprehensive genomic profiling in cancer treatment.
Founding members of PMEC include The Cleveland Clinic’s Taussig Cancer Institute, Hackensack University Medical Center, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Sidney Kimmel Cancer Center at Thomas Jefferson University, UC Davis Health Comprehensive Cancer Center, the University of North Carolina Lineberger Comprehensive Cancer Center, and Vanderbilt-Ingram Cancer Center and The Wake Forest Baptist Comprehensive Cancer Center.
“The promise of precision medicine rests on these national and international initiatives, including PMEC, which enable investigators to share crucial data. Only through that data sharing can we understand the implications of genomics for patient care,” said Mary Zutter, M.D., assistant vice chancellor for Integrative Diagnostics at Vanderbilt University Medical Center in today’s statement.
PMEC is being established on the guiding principles of innovation, education, and the exchange of highly validated molecular information and outcomes data to improve cancer care. PMEC members will have access to a suite of innovative information tools and programs tailored to fit the needs of the individual cancer centers who are members of PMEC.
A selection of these planned offerings include:
• access to a shared data exchange platform of de-identified, matched clinical outcomes and genomic data contributed by Foundation Medicine and PMEC members to support research and clinical innovation;
• access to clinical research programs that integrate comprehensive genomic profiling to improve cancer care; and
• programs to support the advancement of precision medicine and molecular oncology through training, education and streamlined member services.
Additionally, PMEC members can elect to participate in best practices exchanges, where members will have the opportunity to share ideas advancing precision medicine.
“The Precision Medicine Exchange Consortium is being developed as the most comprehensive program of its kind and will align innovators in cancer care around molecular information and clinical data curation and exchange,” said Vincent A. Miller, M.D., chief medical officer at Foundation Medicine in the statement. “Collectively, PMEC is poised to fuel innovation, support cancer research and extend valuable information and education in a way that heretofore has not happened within the cancer community. We’re proud to be launching this initiative with so many thought leaders across a broad spectrum of cancer institutions and practices. We’re actively seeking new members who share PMEC’s vision, and we welcome conversations with additional cancer centers, data and informatics organizations and payers who embrace the opportunity to collaborate for the betterment of cancer care.”